Back to MW MARSHALL WACE, LLP

TRVITRVI
Showing 8 of 12 quarters

Position history for MWMARSHALL WACE, LLP's holdings in Trevi Therapeutics, Inc.

MARSHALL WACE, LLP holds 2.7M shares of TRVI (Trevi Therapeutics, Inc.), worth $49.9M as of 2026-Q2. The position was decreased (-32.6% shares). TRVI represents 0.0% of MARSHALL WACE, LLP's portfolio.

Current Value

$49.9M

Current Shares

2.7M

Total Value Change

+$49.6M

Total Shares Change

+2.6M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
2.7M
-32.6%
$49.9M0.0%$18.65
0
2026-Q1
Decreased
4M
-13.4%
$47.3M0.0%$12.26
0
2025-Q4
Decreased
4.6M
-5.4%
$57.3M0.1%$12.56
0
2025-Q3
Increased
4.8M
+95.4%
$44.3M0.0%$8.95
47
2025-Q2
Decreased
2.5M
-3.0%
$13.6M0.0%$5.62
0
2025-Q1
Increased
2.6M
+5851.0%
$16.1M0.0%$6.50
45
2024-Q4
Decreased
42,921
-47.1%
$176,8350.0%$4.10
0
2024-Q3
New
81,124
-
$270,9540.0%$3.33
32

Other major holders of TRVI: FMR LLC, BlackRock, Inc., WELLINGTON MANAGEMENT GROUP LLP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used